Pharmaceuticals

The Michael J. Fox Foundation and Parkinson’s UK award $5.2 million to Mission Therapeutics to research potential treatments for Parkinson’s disease

bexib
By bexib 0 Min Read

MTX325 is in Phase I trials and is thought to be able to alter the course of the disease.

You Might Also Like

Parkinson’s Foundation Announces Grants for Community Programs Across 40 States

Sarculisa combination improves progression-free survival in newly diagnosed transplant-ineligible multiple myeloma patients

Repairing the Spine: Q&A with NervGen CEO Mike Kelly

FDA approves Biocon Biologics’ Eylea biosimilar Yesafili to treat multiple eye diseases

US Pharma and Biotech Summit 2024: Biotech Industry Overview

Share This Article
Previous Article Bitcoin Plummets to $57K, Solana Plummets 8% in One Day (MarketWatch) – Investorempires.com
Next Article Nigeria plans to develop research centre focusing on blockchain and emerging technologies – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Cost and ROI of smart farming in India with break-even analysis
Agro Businesses
Capella Hotel Group creates meaningful moments of tradition to celebrate Chinese New Year
Hospitality & Tourism
AI M&A deals expected to increase in 2025
Banking
Remember American Giant’s $12.98 Walmart T-shirt? They made money.
Manufacturing